[FILM-Users 00387] Fwd: Talk on multiphoton NADH and FAD imaging on 8th July

[Martin Spitaler]

...forwarded for your information....

Martin


-------- Original Message --------
Subject: 	Talk on multiphoton NADH and FAD imaging on 8th July
Date: 	Thu, 27 Jun 2013 17:41:01 +0100
From: 	Dunsby, Christopher W <christopher.dunsby at imperial.ac.uk>
To: 	Spitaler, Martin <m.spitaler at imperial.ac.uk>



Dear Martin,

You might be interested in the talk below from Alex Walsh who is in 
Melissa Skala's group at Vanderbilt University. It is scheduled for 1100 
on Monday 8^th July in the Optics Reading Room (Blackett 613).

best regards,

Chris

*From:*alexandra.j.walsh at vanderbilt.edu 
[mailto:alexandra.j.walsh at vanderbilt.edu] *On Behalf Of *Alex Walsh
*Sent:* 26 June 2013 21:43
*To:* Dunsby, Christopher W
*Cc:* Kelly, Douglas J; French, Paul (PHOT) M W (Photonics); Melissa Skala
*Subject:* Re: Alex's July visit

Yes, title and abstract are below.


Optical metabolic imaging predicts anti-cancer therapeutic response

The drug combination that is chosen for cancer patients is determined 
from histological markers of receptor expression.  Unfortunately, many 
patients do not respond to chemotherapy, and therefore face a greater 
risk of recurrence and death.  No current technologies can accurately 
predict individual tumor response to particular drugs.  Cellular 
metabolism is a potentially powerful marker of tumor response to 
treatment, because the oncogenic drivers targeted by therapeutic agents 
often regulate cellular metabolism.  In this study, we demonstrate the 
sensitivity of optical metabolic imaging to predict therapeutic response 
in xenografts /in vivo/,//and//in primary patient tumor derived 
organoids, in both breast cancer and pancreatic cancer models.  We 
utilize mulitphoton fluorescence intensity and fluorescence lifetime 
imaging to probe cellular NADH and FAD, two coenzymes of metabolism. 
   Endpoints of cellular metabolism include the optical redox ratio 
(NADH fluorescence intensity divided by that of FAD) the mean 
fluorescence lifetime of NADH, and the mean fluorescence lifetime of 
FAD. Upon treatment with estrogen receptor inhibitors and human 
epidermal growth factor receptor inhibitors, the redox ratio of 
responsive tumors decreases (p<0.001) and is further reduced when 
effective therapies are combined (p<0.001).  Furthermore, the NADH 
fluorescence lifetime decreases in organoids treated with human 
epidermal growth factor receptor inhibitors (p<0.05).  With these 
findings, optical metabolic imaging shows potential for development into 
a high-throughput screen to test the efficacy of a panel of drugs to 
direct clinical therapy selection and expedite pre-clinical studies.

Alex Walsh



-------------- next part --------------
HTML attachment scrubbed and removed